Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Raje, Noopur; Terpos, Evangelos; Willenbacher, Wolfgang; Shimizu, Kazuyuki; García‐Sanz, Ramón; Durie, Brian G.M.; Legieć, Wojciech; Krejčí, Marta; Laribi, Kamel; Zhu, Li; Cheng, Paul; Warner, Douglas; Roodman, G. David

doi:10.1016/s1470-2045(18)30072-x

Cited by 313 publications

(384 citation statements)

References 27 publications

Supporting

Mentioning

360

Contrasting

Unclassified

Order By: Relevance

“…In a recent study, Roodman and colleagues found that denosumab has non‐inferiority for the prevention of skeletal‐related events in multiple myeloma patients when compared with zoledronic acid, the mainstay therapy for this patient population. This study also provided clinical evidence of a potential anti‐myeloma effect based on RANKL inhibition . Based on these promising results, it is expected that denosumab becomes an additional option for treatment of myeloma patients with bone disease.…”

Section: Osteocytes and Their Derived Factors As Targets For The Treamentioning

confidence: 63%

The Emerging Role of Osteocytes in Cancer in Bone

Atkinson

Delgado‐Calle

2019

JBMR Plus

View full text Add to dashboard Cite

Advances in the last decade have established the osteocyte, the most abundant cell in bone, as a dynamic and multifunctional cell capable of controlling bone homeostasis by regulating the function of both osteoblasts and osteoclasts. In addition, accumulating evidence demonstrates that osteocyte function is altered in several skeletal disorders, and targeting osteocytes and their derived factors improves skeletal health. Despite the remarkable progress in our understanding of osteocyte biology, there has been a paucity of information regarding the role of osteocytes in the progression of cancer in bone. Exciting, recent discoveries suggest that tumor cells communicate with osteocytes to generate a microenvironment that supports the growth and survival of cancer cells and stimulates bone destruction. This review features these novel findings and discussions regarding the impact of chemotherapy on osteocyte function and the potential of targeting osteocytes for the treatment of cancer in bone. © 2019 The Authors. JBMR Plus published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research.

show abstract

Section: Osteocytes and Their Derived Factors As Targets For The Treamentioning

confidence: 63%

The Emerging Role of Osteocytes in Cancer in Bone

Atkinson

Delgado‐Calle

2019

JBMR Plus

View full text Add to dashboard Cite

show abstract

“…Although zoledronic acid is not recommended for patients with severe renal injury, reduced‐dose pamidronate is feasible . The recently approved RANK ligand inhibitor denosumab may be an additional option for these patients …”

Section: Discussionmentioning

confidence: 99%

Underutilization of guideline‐recommended supportive care among older adults with multiple myeloma in the United States

Giri

Zhu

Wang

et al. 2019

Cancer

View full text Add to dashboard Cite

Background With improving survival for patients with multiple myeloma (MM), supportive care that is focused on optimizing quality of life and minimizing treatment‐related toxicities is increasingly important. The extent to which patients with MM are receiving recommended supportive care is unknown. Methods This study used the Surveillance, Epidemiology, and End Results–Medicare database to identify older adults (age ≥66 years) diagnosed with MM in 2008‐2013 who had received active treatment and survived 1 year or longer after their diagnosis. Outcomes of interest included guideline‐recommended supportive care, which was defined as 1) bone‐modifying drugs (BMDs) within the 12 months after the diagnosis, 2) influenza vaccination in the first season after the diagnosis, and 3) concomitant use of prophylactic antivirals with proteasome inhibitors. Multivariable logistic regression models were used to evaluate associations between patient/facility‐level characteristics and supportive care use. Results Among 1996 patients receiving MM‐directed therapy, 64%, 52%, and 49% received BMDs, an influenza vaccination, and antiviral prophylaxis, respectively. Non‐Hispanic black patients (odds ratio [OR] vs white patients, 0.63; 95% confidence interval [CI], 0.46‐0.88) and patients with baseline renal impairment (OR, 0.43; 95% CI, 0.34‐0.54) had lower odds of BMDs. Non‐Hispanic blacks (OR, 0.52; 95% CI, 0.37‐0.73) and those with dual Medicaid enrollment (OR, 0.76; 95% CI, 0.58‐0.99) had lower odds of influenza vaccination. Treatment in a community‐based setting was associated with reduced odds of antiviral prophylaxis (OR, 0.58; 95% CI, 0.46‐0.72). Conclusions Substantial underutilization of guideline‐recommended supportive care was observed among older adults with MM in the United States, and this was associated with both patient and facility characteristics. Targeted interventions are needed to improve supportive care for patients with MM.

show abstract

“…322e324 This medication under the trade name Xgeva is also used to prevent skeletal-related events in adults with bone metastasis from breast, prostate cancers, and multiple myeloma. 325,326…”

Section: Hypophosphatemiamentioning

confidence: 99%